- Home
- COLL vs DAO Comparison
COLL vs DAO Comparison
Compare COLL & DAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- DAO
- Stock Information
- Founded
- COLL 2002
- DAO 2006
- Country
- COLL United States
- DAO China
- Employees
- COLL N/A
- DAO N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- DAO Other Consumer Services
- Sector
- COLL Health Care
- DAO Real Estate
- Exchange
- COLL Nasdaq
- DAO Nasdaq
- Market Cap
- COLL 910.2M
- DAO 884.4M
- IPO Year
- COLL 2015
- DAO 2019
- Fundamental
- Price
- COLL $29.05
- DAO $7.76
- Analyst Decision
- COLL Strong Buy
- DAO
- Analyst Count
- COLL 5
- DAO 0
- Target Price
- COLL $43.60
- DAO N/A
- AVG Volume (30 Days)
- COLL 438.9K
- DAO 134.4K
- Earning Date
- COLL 05-08-2025
- DAO 05-22-2025
- Dividend Yield
- COLL N/A
- DAO N/A
- EPS Growth
- COLL 43.56
- DAO N/A
- EPS
- COLL 1.86
- DAO 0.10
- Revenue
- COLL $631,449,000.00
- DAO $770,768,861.00
- Revenue This Year
- COLL $20.00
- DAO $12.62
- Revenue Next Year
- COLL $3.93
- DAO $11.81
- P/E Ratio
- COLL $15.63
- DAO $83.52
- Revenue Growth
- COLL 11.41
- DAO 4.39
- 52 Week Low
- COLL $27.28
- DAO $2.86
- 52 Week High
- COLL $42.29
- DAO $11.82
- Technical
- Relative Strength Index (RSI)
- COLL 43.65
- DAO 43.54
- Support Level
- COLL $29.01
- DAO $7.48
- Resistance Level
- COLL $30.53
- DAO $8.19
- Average True Range (ATR)
- COLL 0.88
- DAO 0.47
- MACD
- COLL -0.01
- DAO -0.03
- Stochastic Oscillator
- COLL 20.97
- DAO 27.22
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About DAO Youdao Inc. each representing one
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and Youdao Pocket Translator.